|
|
Volumn 27, Issue 4, 2009, Pages 479-480
|
|
Variations on the fludarabine, cyclophosphamide, and rituximab combination in chronic lymphocytic leukemia therapy: What have we learned?
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
CYCLOPHOSPHAMIDE;
FLUDARABINE;
LENALIDOMIDE;
RITUXIMAB;
ANEMIA;
CANCER COMBINATION CHEMOTHERAPY;
CANCER IMMUNOTHERAPY;
CANCER SURVIVAL;
CHRONIC LYMPHATIC LEUKEMIA;
CLINICAL TRIAL;
DRUG DOSE ESCALATION;
DRUG DOSE INCREASE;
DRUG DOSE REDUCTION;
DRUG DOSE REGIMEN;
DRUG DOSE SEQUENCE;
DRUG EFFICACY;
EDITORIAL;
FEVER;
HIGH RISK PATIENT;
HUMAN;
MULTIPLE CYCLE TREATMENT;
NEUTROPENIA;
OVERALL SURVIVAL;
PRIORITY JOURNAL;
THROMBOCYTOPENIA;
TREATMENT OUTCOME;
ANTIBODIES, MONOCLONAL;
ANTINEOPLASTIC AGENTS;
ANTINEOPLASTIC AGENTS, ALKYLATING;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
CLINICAL TRIALS, PHASE II AS TOPIC;
CYCLOPHOSPHAMIDE;
HUMANS;
LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL;
TREATMENT OUTCOME;
VIDARABINE;
|
|
EID: 59149089558
PISSN: 0732183X
EISSN: None
Source Type: Journal
DOI: 10.1200/JCO.2008.18.8698 Document Type: Editorial |
|
Times cited : (7)
|
|
References (4)
|
